# A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

> **NCT05662020** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Beijing Health Guard Biotechnology, Inc** · enrollment: 2750 (actual)

## Conditions studied

- Human Papillomavirus Infection

## Interventions

- **BIOLOGICAL:** Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)
- **BIOLOGICAL:** GARDASIL® 9

## Key facts

- **NCT ID:** NCT05662020
- **Lead sponsor:** Beijing Health Guard Biotechnology, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-23
- **Primary completion:** 2022-11-07
- **Final completion:** 2028-03-23
- **Target enrollment:** 2750 (ACTUAL)
- **Last updated:** 2022-12-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05662020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05662020, "A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05662020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*